Brought to you by 
EyeTech closes $108.5mm Series C placement
30 Dec 2002
Executive Summary
EyeTech Pharmaceuticals Inc. (eye disease drugs) could raise as much as $108.5mm in a two-tranche private placement of Series C preferred stock led by JP Morgan Partners. Other investors were BB Biotech, MPM Capital, Alta Partners, Schroder Ventures, and Merrill Lynch. The first half of the financing is payable immediately; the second $54.2mm is payable on the completion of enrollment of the two pivotal Phase III trials of its lead product, Macugen, for age-related macular degeneration (AMD).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EyeTech closes $108.5mm Series C placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice